| Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 S Rost, A Fregin, V Ivaskevicius, E Conzelmann, K Hörtnagel, HJ Pelz, ... Nature 427 (6974), 537-541, 2004 | 1494 | 2004 |
| Emicizumab prophylaxis in hemophilia A with inhibitors J Oldenburg, JN Mahlangu, B Kim, C Schmitt, MU Callaghan, G Young, ... New England Journal of Medicine 377 (9), 809-818, 2017 | 1080 | 2017 |
| Emicizumab prophylaxis in patients who have hemophilia A without inhibitors J Mahlangu, J Oldenburg, I Paz-Priel, C Negrier, M Niggli, ME Mancuso, ... New England Journal of Medicine 379 (9), 811-822, 2018 | 684 | 2018 |
| The genetic basis of resistance to anticoagulants in rodents HJ Pelz, S Rost, M Hünerberg, A Fregin, AC Heiberg, K Baert, ... Genetics 170 (4), 1839-1847, 2005 | 440 | 2005 |
| Haemophilia A: mutation type determines risk of inhibitor formation R Schwaab, HH Brackmann, C Meyer, J Seehafer, M Kirchgesser, ... Thrombosis and haemostasis 74 (12), 1402-1406, 1995 | 435 | 1995 |
| F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis SC Gouw, HM van den Berg, J Oldenburg, J Astermark, PG de Groot, ... Blood, The Journal of the American Society of Hematology 119 (12), 2922-2934, 2012 | 427 | 2012 |
| Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens J Oldenburg Blood, The Journal of the American Society of Hematology 125 (13), 2038-2044, 2015 | 377 | 2015 |
| VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation C Geisen, M Watzka, K Sittinger, M Steffens, L Daugela, E Seifried, ... Thrombosis and haemostasis 94 (10), 773-779, 2005 | 360 | 2005 |
| Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study SC Gouw, HM van den Berg, K Fischer, G Auerswald, M Carcao, ... Blood, The Journal of the American Society of Hematology 121 (20), 4046-4055, 2013 | 358 | 2013 |
| Genetic risk factors for inhibitors to factors VIII and IX J Oldenburg, A Pavlova Haemophilia 12, 15-22, 2006 | 350 | 2006 |
| Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A J Astermark, J Oldenburg, A Pavlova, E Berntorp, AK Lefvert, ... Blood 107 (8), 3167-3172, 2006 | 339 | 2006 |
| A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors G Young, RI Liesner, T Chang, R Sidonio Jr, J Oldenburg, ... Blood, The Journal of the American Society of Hematology 134 (24), 2127-2138, 2019 | 335 | 2019 |
| Gender specific differences in levels of DNA methylation at selected loci from human total blood: a tendency toward higher methylation levels in males O El-Maarri, T Becker, J Junen, SS Manzoor, A Diaz-Lacava, R Schwaab, ... Human genetics 122, 505-514, 2007 | 329 | 2007 |
| Immune Tolerance for the Treatment of Factor VIII Inhibitors‐Twenty Years'‘Bonn Protocol’ HH Brackmann, J Oldenburg, R Schwaab Vox Sanguinis 70, 30-35, 1996 | 317 | 1996 |
| Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: guidance statement from the GTH J Oldenburg, R Klamroth, F Langer, M Albisetti, C Von Auer, C Ay, ... Hämostaseologie 41 (03), 184-189, 2021 | 298 | 2021 |
| Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A J Astermark, J Oldenburg, J Carlson, A Pavlova, K Kavakli, E Berntorp, ... Blood 108 (12), 3739-3745, 2006 | 290 | 2006 |
| The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development J Astermark, E Berntorp, GC White, BL Kroner, MIBS Study Group Haemophilia 7 (3), 267-272, 2001 | 289 | 2001 |
| Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic … H Pfeifer, B Wassmann, A Pavlova, L Wunderle, J Oldenburg, ... Blood, The Journal of the American Society of Hematology 110 (2), 727-734, 2007 | 280 | 2007 |
| Haemophilia A: from mutation analysis to new therapies J Graw, HH Brackmann, J Oldenburg, R Schneppenheim, M Spannagl, ... Nature Reviews Genetics 6 (6), 488-501, 2005 | 275 | 2005 |
| Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A CL Eckhardt, AS Van Velzen, M Peters, J Astermark, PP Brons, ... Blood, The Journal of the American Society of Hematology 122 (11), 1954-1962, 2013 | 259 | 2013 |
